INBJUDAN TILL TECKNING AV UNITS I PILA PHARMA AB (PUBL)
RIGHT ISSUE OF UNITS - SUBSCRIPTION PERIOD 1-15 JULY
Subscription period 1 – 15 July 2025
THE OFFER IN SUMMARY
Last day of trading in shares including right to receive unit rights: 25 June 2025
First day of trading in shares excluding right to receive unit rights: 26 June 2025
Record date for the Rights Issue: 27 June 2025
Trading in unit rights: 1 – 10 July 2025
Subscription period: 1 – 15 July 2025
Trading in paid subscribed unit (BTU): 1 July 2025 – 4 August 2025
Expected announcement of the preliminary outcome in the Rights Issue: 17 July 2025
Expected first day of trading in shares: 6 August 2025
Subscription period for warrants of series TO2: 5 – 15 February 2026
Subscription rights: Those who on the record date 27 June 2025 are registered as shareholders in PILA PHARMA will receive:
- One (1) unit rights for each one share held.
- Nineteen (19) unit rights will entitle to subscription for seven (7) units, consisting of one (1) newly issued share and one (1) new warrant of series TO2.
The offer: 9,994,019 units
Price: SEK 2.00 per unit
Market place: Nasdaq First North Growth Market
FOR INVESTORS WHO HOLD SUBSCRIPTION RIGHTS
If you hold subscription rights, it will be possible to partake in the rights issue directly on the different trading platforms.
Below are links to the most common platforms – if your chosen bank / platform is not listed we advise you to get in touch with them and inform the company ISIN number: SE0015988274.
Denmark
Sweden
Nordnet Sverige
https://www.nordnet.se
+46 10-583 3000
Monday-Friday (08:30-18:00 CET)
FOR INVESTORS WHO DON’T HOLD SUBSCRIPTION RIGHTS
For investors who don’t hold subscription rights, it is recommended to confirm interest directly with the issuing agent, Nordic Issuing.
On the dedicated landing page, it is possible to register interest in the rights issue of units, without subscription rights. The way to register interest is through digital signature log-in.
Read more about the offer via this QR code or through this link.
If you endure any issues, or if you have any questions regarding how to subscribe via email or phone, please contact the issuing agent, Nordic Issuing
Amanda Gustafsson
Head of Operations
ISSUING INSTITUTION
Nordic Issuing
nordic-issuing.se
LEGAL COUNSEL
MAQS Advokatbyrå
This is a brief introduction on how to sign for units without unit rights in the ongoing rights issue with PILA PHARMA, concluding on July 15, 2025 at 23:59 CET.
If you are an investor without unit rights, this video will go through the steps of how to sign for units through our issuing agent Nordic Issuing.
Find the link to the video (In English) here
SIT-DOWN INTERVIEW WITH FINWIRE TALKING FUNDRAISING AND BET ON OBESITY [July 04, 2025]
CEO Gustav H. Gram begins by introducing the PILA PHARMA ‘oral solution for obesity, a TRPV1-antagonist, a very different target to other drugs in development for obesity and diabetes. He emphasizes how the obesity market has grown tremendously and is increasingly looking to fragment and how oral solutions will be key to address the huge volume of people living with overweight globally.
He also talks about their ongoing rights issue of units, where the company wish to fund dedicated obesity studies in rats and humans living with overweight. With the issue quite remarkably covered by pre-commitments to 99,87%, and why PILA PHARMA may present an attractive opportunity for investors in a market segment with estimates of more than 1 billion people living with obesity and value estimates of more than $100 billion annually by 2030.
Find the link to the video (In English) here
INTERVIEW ON RIGHTS ISSUE AND BET ON OBESITY WITH DIREKT STUDIOS [July 04, 2025]
PILA PHARMA’s CEO Gustav H. Gram discusses the ongoing rights issue together with Mathias Vahlne from Swedish financial media outlet, Direkt Studios, an issue which is which is covered by existing investors and guarantor pre-commitments to 99,87%.
PILA PHARMA wishes to use the proceeds to fund a venture into pure obesity studies with emphasis on achieving a comprehensive and meaningful data package that can facilitate a partnership. The Company’s overall aspirations remain to develop a new oral drug for obesity and diabetes treatment based on TRPV1 inhibition.
Find the link to the video (In English) here
Ongoing rights issue and bet on obesity with investment podcast 10x [July 3, 2025]
CEO Gustav H. Gram shares exciting updates on the company’s rights issue where the share offering, which is already 99% secured, and the proceeds will fuel a new venture in obesity with their promising pill treatment.
Find the link to the video (In English) here
“Der er noget helt usædvanligt ved den her kapitalrejsning, og det er jo at den er forhåndsgaranteret til 100%” – Helge Larsen
PILA PHARMA og adm. direktør Gustav Hanghøj Gram har været tilbage hos ProInvestor og snakke om den store tilslutning og opbakning til vores kapitalrejsning der skal finansiere nye dedikerede fedme studier med PILA PHARMA’s tablet baseret på TRPV1 hæmning – en helt ny og anderledes fremgangsmåde!
Find the link to the video (In Danish) here
Fedmemarkedet handler primært om glp1, senere er amylin blevet kendt, men det dansk-svenske biotekselskab Pila Pharma, grundlagt af Dorte X. Gram med rødder i Novo Nordisk, udvikler en oral behandling mod type 2-diabetes og fedme baseret på en såkaldt chili-receptor. Hør mere i denne video, hvor Helge Larsen har besøg af Dorte X. Gram.
Find the link to the video (In Danish) here